Related Experiment Video
Updated: Jul 11, 2026

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture
Published on: December 22, 2016
Efficacy and Safety of Electroacupuncture on Insomnia in Parkinson's Disease: A Multicentre, Randomized, Controlled
Si-Chun Gu1, Ping Yin2, Min Yang3
1Department of Neurology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Background:
Sleep disturbances, particularly insomnia, are prevalent and debilitating non-motor symptoms of Parkinson's disease (PD), significantly impacting quality of life. Current treatment options are limited by side effects and accessibility. Electroacupuncture (EA), a non-pharmacological approach, has shown promise in insomnia, while its specific impact on insomnia in PD remains unexplored.
Objectives:
To determine the efficacy and safety of EA vs sham electroacupuncture (SA) on insomnia associated with PD.
Methods:
We conducted a multicenter, participant-and assessor-blinded, randomized, sham-controlled clinical trial from March 1, 2024, to October 28, 2024, across eight sites in China. A total of 136 PD patients with insomnia were assigned to receive EA or SA (68 per arm) over an 8-week treatment period followed by a 12-week follow-up period. The primary outcome was the change in Parkinson's Disease Sleep Scale (PDSS) scores at week 8. A range of subjective sleep-related metrics and objective sleep assessments derived from polysomnography were utilized as secondary outcomes.
Results:
Both groups showed significant improvements in PDSS scores, with the EA group demonstrating a greater effect (between-group difference, 13.50 [95%CI, 12.68 to 14.32]). Secondary outcomes, including Insomnia Severity Index, Epworth Sleepiness Scale, and polysomnography-derived parameters, also showed greater improvements in EA group. The effects were maintained during the 12-week follow-up with no severe adverse events. The blinding assessment confirmed successful blinding.
Conclusions:
EA was effective in improving insomnia and related sleep disturbances in PD. This study provided Class I evidence supporting the integration of EA into the treatment regimen for insomnia in PD.
More Related Videos
Related Concept Videos
Blind Procedures
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

